Kauppalehti15h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Dr. Frank Mathias, Chief Executive Officer of OXB, said, “We are delighted that Boehringer Ingelheim is using OXB’s proprietary lentiviral vector manufacturing technology, to produce lentiviral vector ...